Skip to main content
SpringerLink
Log in

Leitlinie Nr. 24a Uveitis intermedia

Guidelines nr. 24a intermediate uveitis

  • Leitlinien, Stellungnahmen und Empfehlungen
  • Published:
Der Ophthalmologe Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2
Abb. 3

Abbreviations

BVA:

Berufsverband der Augenärzte Deutschlands

DGKJRh:

Deutsche Gesellschaft für Kinder- und Jugendrheumatologie

DOG:

Deutsche Ophthalmologische Gesellschaft

EVER:

European Association für Vison and Eye Research

NVL:

Nationale VersorgungsLeitlinien

Literatur

  1. Jabs DA, Nussenblatt RB, Rosenbaum JT (2005) Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol 140:509–516

    PubMed  Google Scholar 

  2. Suhler EB, Lloyd MJ, Choi D et al (2008) Incidence and prevalence of uveitis in Veterans Affairs Medical Centers of the Pacific Northwest. Am J Ophthalmol 146:890–896

    PubMed  Google Scholar 

  3. Darrell RW, Wagener HP, Kurland LT (1962) Epidemiology of uveitis. Incidence and prevalence in a small urban community. Arch Ophthalmol 68:502–514

    CAS  PubMed  Google Scholar 

  4. Gritz DC, Wong IG (2004) Incidence and prevalence of uveitis in Northern California; the Northern California Epidemiology of Uveitis Study. Ophthalmology 111:491–500

    PubMed  Google Scholar 

  5. Mortensen KK, Goldschmidt E (1981) Uveitis. Eine epidemiologische Untersuchung. Ber Zusammenkunft Dtsch Ophthalmol Ges 78: p:97–101

    Google Scholar 

  6. Vadot E (1992) Epidemiology of intermediate uveitis: a prospective study in Savoy. Dev Ophthalmol 23:33–34

    CAS  PubMed  Google Scholar 

  7. Tran VT, Auer C, Guex-Crosier Y et al (1994) Epidemiological characteristics of uveitis in Switzerland. Int Ophthalmol 18:293–298

    PubMed  Google Scholar 

  8. Saari KM, Päivönsalo-Hietanen T, Vaahtoranta-Lehtonen H et al (1995) Epidemiology of endogenous uveitis in south-western Finland. Acta Ophthalmol 73:345–349

    CAS  Google Scholar 

  9. Miettinen R (1977) Incidence of uveitis in Northern Finland. Acta Ophthalmol 55:252–260

    CAS  Google Scholar 

  10. Manthey KF (1988) Intraokuläre Entzündungen. Ferdinand Enke Verlag, Stuttgart

    Google Scholar 

  11. Jakob E, Reuland MS, Mackensen F et al (2009) Uveitis subtypes in a german interdisciplinary uveitis center—analysis of 1916 patients. J Rheumatol 36:12736

    Google Scholar 

  12. McCannel CA, Holland GN, Helm CJ et al (1996) Causes of uveitis in the general practice of ophthalmology. UCLA Community-Based Uveitis Study Group. Am J Ophthalmol 121:35–46

    CAS  PubMed  Google Scholar 

  13. Boskovich SA, Lowdere CY, Meisler DM, Gutman FA (1993) Systemic diseases associated with intermediate uveitis. Cleve Clin J Med 60:460–465

    CAS  PubMed  Google Scholar 

  14. Bonfioli AA, Damico FM, Curi AL, Orefice F (2005) Intermediate uveitis. Semin Ophthalmol 20:147–154

    PubMed  Google Scholar 

  15. Vidovic-Valentincic N, Kraut A, Hawlina M et al (2009) Intermediate uveitis: long-term course and visual outcome. Br J Ophthalmol 93:477–480

    CAS  PubMed  Google Scholar 

  16. Heinz C, Schoonbrood S, Heiligenhaus A (2014) Intermediate uveitis in children and young adults: differences in clinical course, associations and visual course. Br J Ophthalmol 98:1107–1111

    PubMed  Google Scholar 

  17. Ness T, Boehringer D, Heinzelmann S (2017) Intermediate uveitis: pattern of etiology, complications, tretment and outcome in a tertiary academic center. Orphanet J Rare Dis 12:81

    PubMed  PubMed Central  Google Scholar 

  18. Malinowski SM, Pulido JS, Folk JC (1993) Long-term visual outcome and complications associated with pars planitis. Ophthalmology 100:818–824

    CAS  PubMed  Google Scholar 

  19. Stübiger N, Ruprecht K, Pleyer U (2018) Intraocular inflammation in multiple sclerosis. Ophthalmologe 115:531–542

    PubMed  Google Scholar 

  20. Fearnley IR, Rosenthal AR (1995) Fuchs’ heterochromic iridocyclitis revisited. Acta Ophthalmol Scand 73:166–170

    CAS  PubMed  Google Scholar 

  21. Jones NP (1991) Fuchs’ heterochromic uveitis: a reappraisal of the clinical spectrum. Eye (Lond) 5:649–661

    Google Scholar 

  22. Mandeville JT, Levinson RD, Holland GN (2001) The tubulointerstitial nephritis and uveitis syndrome. Surv Ophthalmol 46:195–208

    CAS  PubMed  Google Scholar 

  23. Donaldson MJ, Pulido JS, Herman DC et al (2007) Pars planitis: a 20-year study of incidence, clinical features, and outcomes. Am J Ophthalmol 144:812–817

    PubMed  Google Scholar 

  24. Niederer RL, Sharief L, Bar A et al (2017) Predictors of long-term visual outcome in intermediate uveitis. Ophthalmology 124:393–398

    PubMed  Google Scholar 

  25. Nussenblatt RB, Palastine AG, Chan CC, Roberge F (1985) Standardization of vitreal inflammatory activity in intermediate and posterior uveitis. Ophthalmology 92:467–471

    CAS  PubMed  Google Scholar 

  26. Tugal-Tutkun I, Herbort CP, Khairallah M et al (2010) Scoring of dual fluorescein and ICG inflammatory angiographic signs for the grading of posterior segment inflammation (dual fluorescein and ICG angiographic scoring system for uveitis). Int Ophthalmol 30:539–552

    PubMed  Google Scholar 

  27. Quentin CD, Reiber H (2004) Fuchs heterochromic cyclitis: rubella virus antibodies and genome in aqueous humor. Am J Ophthalmol 138:46–54

    PubMed  Google Scholar 

  28. de Groot-Mijnes JD, de Visser L, Rothova A et al (2006) Rubella virus is associated with fuchs heterochromic iridocyclitis. Am J Ophthalmol 141:212–214

    PubMed  Google Scholar 

  29. Ang M, Hedayatfar A, Zhang R, Chee SP (2012) Clinical signs of uveitis associated with latent tuberculosis. Clin Experiment Ophthalmol 40:689–696

    PubMed  Google Scholar 

  30. Ruokonen PC, Metzner S, Ucer A et al (2010) Intraocular antibody synthesis against rubella virus and other microorganisms in Fuchs’ heterochromic cyclitis. Graefes Arch Clin Exp Ophthalmol 248:565–571

    PubMed  Google Scholar 

  31. Fox CP, Phillips EH, Smith J, Linton K, Gallop-Evans E, Hemmaway C, Auer DP, Fuller C, Davies AJ, McKay P, Cwynarski K (2019) Guidelines for the diagnosis and management of primary central nervous system diffuse large B‑cell lymphoma. British Society for Haematology. Br J Haematol 184:348–363

    PubMed  Google Scholar 

  32. Roesel M, Gutfleisch M, Heinz C et al (2009) Intravitreal and orbital floor triamcinolone acetonide injections in noninfectious uveitis: a comparative study. Ophthalmic Res 42:81–86

    CAS  PubMed  Google Scholar 

  33. Gaudio PA (2004) A review of evidence guiding the use of corticosteroids in the treatment of intraocular inflammation. Ocul Immunol Inflamm 12:169–192

    CAS  PubMed  Google Scholar 

  34. Bae JH, Lee CS, Lee SC (2011) Efficacy and safety of intravitreal bevacizumab compared with intravitreal and posterior sub-tenon triamcinolone acetonide for treatment of uveitic cystoid macular edema. Retina 31:111–118

    CAS  PubMed  Google Scholar 

  35. Kok H, Lau C, Maycook N et al (2005) Outcome of intravitreal triamcinolone in uveitis. Ophthalmology 112:1916 e1–1916 e7

    Google Scholar 

  36. Angunawela RI, Heatley CJ, Williamson TH et al (2005) Intravitreal triamcinalone acetonide for refractory uveitic cystoid macular oedema: longterm management and outcome. Acta Ophthalmol Scand 83:595–599

    CAS  PubMed  Google Scholar 

  37. Lowder C, Belfort R Jr, Lightman S et al (2011) Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Arch Ophthalmol 129:545–553

    PubMed  Google Scholar 

  38. Winterhalter S, Ruokonen P, van der Velden KH et al (2011) Intravitreal implants: drug carriers and carriers of hope? Ophthalmologe 108:222–229

    CAS  PubMed  Google Scholar 

  39. Winterhalter S, Behrens UD, Salchow D, Joussen AM, Pleyer U (2017) Dexamethasone implants in paediatric patients with noninfectious intermediate or posterior uveitis: first prospective exploratory case series. BMC Ophthalmol 17:252

    PubMed  PubMed Central  Google Scholar 

  40. Tufail A, Lightman S, Kamal A et al (2018) Post-marketing surveillance study of the safety of dexamethasone intravitreal implant in patients with retinal vein occlusion or noninfectious posterior segment uveitis. Clin Ophthalmol 12:2519–2534

    CAS  PubMed  PubMed Central  Google Scholar 

  41. Pohlmann D, Vom Brocke GA, Winterhalter S et al (2018) Dexamethasone inserts in noninfectious uveitis: a single-center experience. Ophthalmology 125:108899

    Google Scholar 

  42. Jaffe GJ, Lin P, Keenan RT et al (2016) Injectable fluocinolone acetonide long-acting implant for noninfectious intermediate uveitis, posteriore uveitis, and panuveitis. Ophthalmology 123:1940–1948

    PubMed  Google Scholar 

  43. Jaffe GJ, Foster CS, Pavesio CE et al (2019) Effect of an injectable fluocinolone acetonide insert on recurrence rates in chronic noninfectious uveitis affecting the posterior segment: twelve-month results. Ophthalmology 126:601–610

    PubMed  Google Scholar 

  44. Pouwels XGLV, Petersohn S, Carrera VH et al (2019) Fluocinolone acetonide intravitreal implant for treating recurrent non-infectious uveitis: an evidence review group perspective of a NICE single technology appraisal. PharmacoEconomics. https://doi.org/10.1007/s40273-019-00851-z

    Article  PubMed  PubMed Central  Google Scholar 

  45. Soheilian M, Rabbanikhah Z, Ramezani A et al (2010) Intravitreal bevacizumab versus triamcinolone acetonide for refractory uveitic cystoid macular edema: a randomized pilot study. J Ocul Pharmacol Ther 26:199–206

    CAS  PubMed  Google Scholar 

  46. Lasave AF, Schlaen A, Zeballos DG et al (2019) Twenty-four months follow-up of intravitreal bevacizumab injection versus intravitreal triamcinolone acetonide injection for the management of persistent non-infectious uveitic cystoid macular edema. Ocul Immunol Inflamm 27:294–302

    CAS  PubMed  Google Scholar 

  47. Taylor SR, Banker A, Schlaen A et al (2013) Intraocular methotrexate can induce extended remission in some patients in noninfectious uveitis. Retina 33:2149–2154

    CAS  PubMed  Google Scholar 

  48. Khalil HE, El Gendy HA, Youssef HA et al (2016) The effectiveness of intraocular methotrexate in the treatment of posterior uveitis in Behçet’s disease patients compared to retrobulbar steroids injection. J Ophthalmol 2016:1678495

    PubMed  PubMed Central  Google Scholar 

  49. Multicenter uveitis steroid treatment trial research group, Kempen JH, Altaweel MM et al (2010) The multicenter uveitis steroid treatment trial: rationale, design, and baseline characteristics. Am J Ophthalmol 149:550–561

    Google Scholar 

  50. Cunningham ET Jr, Wender JD (2010) Practical approach to the use of corticosteroids in patients with uveitis. Can J Ophthalmol 45:352–358

    PubMed  Google Scholar 

  51. Chirikov VV, Shah R, Kwon Y, Patel D (2019) Oral corticosteroid exposure and increased risk of related complications in patients with noninfectious intermediate, posterior, or panuveitis: Real-world data analysis. Ophthalmic Epidemiol 26:27–46

    PubMed  Google Scholar 

  52. Taylor SR, Isa H, Joshi L, Lightman S (2010) New developments in corticosteroid therapy for uveitis. Ophthalmologica 224(Suppl 1):46–53

    CAS  PubMed  Google Scholar 

  53. Strehl C, Bijlsma JW, De Wit M et al (2016) Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task forcee. Ann Rheum Dis 75:952–957

    CAS  PubMed  Google Scholar 

  54. Dick AD, Rosenbaum JT, Al-Dhibi HA et al (2018) Guidance on noncorticosteroid systemic immunomodulatory therapy in noninfectious uveitis: fundamentals of care for uveitis (FOCUS) initiative. Ophthalmology 125:757–773

    PubMed  Google Scholar 

  55. Whitcup SM, Csaky KG, Podgor MJ et al (1996) A randomized, masked, cross-over trial of acetazolamide for cystoid macular edema in patients with uveitis. Ophthalmology 103:1054–1062

    CAS  PubMed  Google Scholar 

  56. Schilling H, Heiligenhaus A, Laube T et al (2005) Long-term effect of acetazolamide treatment of patients with uveitic chronic cystoid macular edema is limited by persisting inflammation. Retina 25:182–188

    PubMed  Google Scholar 

  57. Pepple KL, Nguyen MH, Pakzad-Vaezi K et al (2019) Response of inflammatory cystoid macular edema to treatment using oral acetazolamide. Retina 39:948–955

    CAS  PubMed  PubMed Central  Google Scholar 

  58. Jabs DA, Rosenbaum JT, Foster CS et al (2000) Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol 130:492–513

    CAS  PubMed  Google Scholar 

  59. Esterberg E, Acharya NR (2012) Corticosteroid-sparing therapy: practice patterns among uveitis specialists. J Ophthalmic Inflamm Infect 2:21–28

    CAS  PubMed  Google Scholar 

  60. Galor A, Jabs DA, Leder HA et al (2008) Comparison of antimetabolite drugs as corticosteroid-sparing therapy for noninfectious ocular inflammation. Ophthalmology 115:1826–1832

    PubMed  Google Scholar 

  61. de Vries J, Baarsma GS, Zaal MJ et al (1990) Cyclosporin in the treatment of severe chronic idiopathic uveitis. Br J Ophthalmol 74:344–349

    PubMed  PubMed Central  Google Scholar 

  62. Kacmaz RO, Kempen JH, Newcomb C et al (2010) Cyclosporine for ocular inflammatory diseases. Ophthalmology 117:576–584

    PubMed  PubMed Central  Google Scholar 

  63. Nussenblatt RB, Palastine AG, Chan CC et al (1991) Randomized, double-masked study of cyclosporine compared to prednisolone in the treatment of endogenous uveitis. Am J Ophthalmol 112:138–146

    CAS  PubMed  Google Scholar 

  64. Murphy CC, Greiner K, Plskova J et al (2005) Cyclosporine vs tacrolimus therapy for posterior and intermediate uveitis. Arch Ophthalmol 123:634–641

    CAS  PubMed  Google Scholar 

  65. Hogan AC, McAvoy CE, Dick AD, Lee RW (2007) Long-term efficacy and tolerance of tacrolimus for the treatment of uveitis. Ophthalmology 114:1000–1006

    PubMed  Google Scholar 

  66. Murphy CC, Greiner K, Plskova J et al (2007) Validity of using vision-related quality of life as a treatment end point in intermediate and posterior uveitis. Br J Ophthalmol 91:154–156

    PubMed  Google Scholar 

  67. Gangaputra S, Newcomb CW, Liesegang TL et al (2009) Methotrexate for ocular inflammatory diseases. Ophthalmology 116:2188–2198

    PubMed  PubMed Central  Google Scholar 

  68. Malik AR, Pavesio C (2005) The use of low dose methotrexate in children with chronic anterior and intermediate uveitis. Br J Ophthalmol 89:806–808

    CAS  PubMed  PubMed Central  Google Scholar 

  69. Rathinam SR, Gonzales JA, Thundikandy R et al (2019) Effect of corticosteroid-sparing treatment with mycophenolate mofetil vs methotrexate on inflammation in patients with uveitis: a randomized clinical trial. JAMA 322:936–945

    CAS  PubMed  PubMed Central  Google Scholar 

  70. Niemeyer KM, Gonzales JA, Rathinam SR et al (2017) Quality of life outcomes from a randomized clinical trial comparing antimetabolites for intermediate, posterior, and panuveitis. Am J Ophthalmol 179:10–17

    PubMed  PubMed Central  Google Scholar 

  71. Teoh SC, Hogan AC, Dick AD, Lee RW (2008) Mycophenolate mofetil for the treatment of uveitis. Am J Ophthalmol 146:752–760

    CAS  PubMed  Google Scholar 

  72. Thorne JE, Jabs DA, Qazi FA et al (2005) Mycophenolate mofetil therapy for inflammatory eye disease. Ophthalmology 112:1472–1477

    PubMed  Google Scholar 

  73. Doycheva D, Zierhut M, Blumenstock G et al (2011) Long-term results of therapy with mycophenolate mofetil in chronic non-infectious uveitis. Graefes Arch Clin Exp Ophthalmol 249:1235–1243

    CAS  PubMed  Google Scholar 

  74. Abu El-Asrar AM, Hemachandran S, Al-Mezaine HS et al (2012) The outcomes of mycophenolate mofetil therapy combined with systemic corticosteroids in acute uveitis associated with Vogt-Koyanagi-Harada disease. Acta Ophthalmol 90:e603–8

    CAS  PubMed  Google Scholar 

  75. Doycheva D, Zierhut M, Blumenstock G et al (2012) Mycophenolate mofetil in the therapy of uveitic macular edema—long-term results. Ocul Immunol Inflamm 20:20311

    Google Scholar 

  76. Lau CH, Comer M, Lightman S (2003) Long-term efficacy of mycophenolate mofetil in the control of severe intraocular inflammation. Clin Experiment Ophthalmol 31:487–491

    PubMed  Google Scholar 

  77. Siepmann K, Huber M, Stübiger N et al (2006) Mycophenolate mofetil is a highly effective and safe immunosuppressive agent for the treatment of uveitis : a retrospective analysis of 106 patients. Graefes Arch Clin Exp Ophthalmol 244:788–794

    CAS  PubMed  Google Scholar 

  78. Deuter CME, Engelmann K, Heiligenhaus A et al (2018) Enteric-coated mycophenolate sodium in the treatment of non-infectious intermeditae uveitis: results of a prospective, controlled, randomised, open-label, early terminated multicentre trial. Br J Ophthalmol 102:647–653

    PubMed  Google Scholar 

  79. Pacheco PA, Taylor SR, Cuchacovich MT, Diaz GV (2008) Azathioprine in the management of autoimmune uveitis. Ocul Immunol Inflamm 16:161–165

    CAS  PubMed  Google Scholar 

  80. Yazici H, Pazarli H, Barnes CG et al (1990) A controlled trial of azathioprine in Behcet’s syndrome. N Engl J Med 322:281–285

    CAS  PubMed  Google Scholar 

  81. Greenwood AJ, Stanford MR, Graham EM (1998) The role of azathioprine in the management of retinal vasculitis. Eye (Lond) 12:783–788

    Google Scholar 

  82. Pasadhika S, Kempen JH, Newcomb CW et al (2009) Azathioprine for ocular inflammatory diseases. Am J Ophthalmol 148:500–509

    CAS  PubMed  PubMed Central  Google Scholar 

  83. Roy M (2007) Early clinical experience with leflunomide in uveitis. Can J Ophthalmol 42:634

    PubMed  Google Scholar 

  84. Molina C, Modesto C, Martin-Begue N, Amal C (2013) Leflunomide, a valid and safe drug for the treatment of chronic anterior uveitis associated with juvenile idiopathic arthritis. Clin Rheumatol 32:1673–1675

    PubMed  Google Scholar 

  85. Bichler J, Benseler SM, Krumrey-Langkammerer M et al (2015) Leflunomide is associated with a higher flare rate compared to methotrexate in the treatment of chronic uveitis in juvenile idiopathic arthritis. Scand J Rheumatol 44:280–283

    CAS  PubMed  Google Scholar 

  86. Levy-Clarke G, Jabs DA, Read RW et al (2014) Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders. Ophthalmology 121:785–796

    PubMed  Google Scholar 

  87. Mackensen F, Max R, Becker MD (2009) Interferons and their potential in the treatment of ocular inflammation. Clin Ophthalmol 3:559–566

    CAS  PubMed  PubMed Central  Google Scholar 

  88. Deuter C, Stubiger N, Zierhut M (2012) Interferon-alphatherapy in noninfectious uveitis. Dev Ophthalmol 51:90–97

    CAS  PubMed  Google Scholar 

  89. Mackensen F, Jakob E, Springer C et al (2013) Interferon versus methotrexate in intermediate uveitis with macular Edema: results of a randomized controlled clinical trial. Am J Ophthalmol. https://doi.org/10.1016/j.ajo.2013.05.002

    Article  PubMed  Google Scholar 

  90. Velazquez-Villoria D, Macia-Badia C, Segura-García A et al (2017) Efficacy of immunomodulatory therapy with interferon‑β or glatiramer acetate on multiple sclerosis-associated uveitis. Arch Soc Esp Oftalmol 92:273–279

    CAS  PubMed  Google Scholar 

  91. Cordero-Coma M, Yilmaz T, Onal S (2013) Systematic Review of Anti-Tumor Necrosis Factor-alpha Therapy for Treatment of Immune-mediated Uveitis. Ocul Immunol Inflamm 21:12–20

    CAS  Google Scholar 

  92. Rubbert-Roth A (2012) Assessing the safety of biologic agents in patients with rheumatoid arthritis. Rheumatol (Oxford) 51(Suppl 5):v38–47

    CAS  Google Scholar 

  93. Suhler EB, Lowder CY, Goldstein DA et al (2013) Adalimumab therapy for refractory uveitis: results of a multicentre, opan-label, prospective trial. Br J Ophthalmol 97:481–486

    PubMed  Google Scholar 

  94. Calvo‑R ío V, Blanco R, Beltrán E et al (2014) Anti-TNF‑α therapy in patients with refractory uveitis due to Behçet’s disease: a 1-year follow-up study of 124 patients. Rheumatol (Oxford) 53:2223–2231

    Google Scholar 

  95. Jaffe GF, Dick AD, Brezin AP et al (2016) Adalimumab in patients with active non-infectious uveitis: VISUAL‑1 Trial. N Engl J Med 375:932–943

    CAS  PubMed  Google Scholar 

  96. Vallet H, Riviere S, Sanna A et al (2015) (French Behç et Network) Efficacy of anti-TNF alpha in severe and/or refractory Behçet’s disease: Multicenter study of 124 patients. J Autoimmun 62:67–74

    CAS  PubMed  Google Scholar 

  97. Nguyen QD, Merrill PT, Jaffe GJ et al (2016) Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial. Lancet 388:1183–1192

    CAS  PubMed  Google Scholar 

  98. Suhler EB, Adan A, Brezin AP et al (2018) Safety and efficacy of adalimumab in patients with noninfectious uveitis in an ongoing open-label study: VISUAL III. Ophthalmology 125:1075–1087

    PubMed  Google Scholar 

  99. Wendling D et al (2014) Comparing the risk of developing uveitis in patients initiating anti-tumor necrosis factor therapy for ankylosing spondylitis: an analysis of a large US claims database. Curr Med Res Opin 30:2515–2521

    CAS  PubMed  Google Scholar 

  100. Maleki A, Sahawneh HF, Ma L et al (2017) Infliximab therapy in patients with noninfectious intermediate uveitis resistant to conventional immunomodulatory therapy. Retina 37:836–843

    CAS  PubMed  Google Scholar 

  101. Markomichelakis NN, Theodossiadis PG, Pantelia E et al (2004) Infliximab for chronic cystoid macular edema associated with uveitis. Am J Ophthalmol 138:648–650

    CAS  PubMed  Google Scholar 

  102. Burmester GR, Landewe R, Genovese MC et al (2017) Adalimumab long-term safety: infections, vaccination response and pregnancy outcomes in patients with rheumatoid arthritis. Ann Rheum Dis 76:414–417

    Google Scholar 

  103. Garcês S, Demengeot J, Benito-Garcia E (2013) The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis. Ann Rheum Dis 72:1947–1955

    PubMed  Google Scholar 

  104. Thomas SS, Borazan N, Barroso N et al (2015) Comparative Immunogenicity of TNF Inhibitors: Impact on Clinical Efficacy and Tolerability in the Management of Autoimmune Diseases. A Systematic Review and Meta-Analysis. BioDrugs 29:241–258

    CAS  PubMed  Google Scholar 

  105. Absasolo L, Rosales Z, Diaz-Valle D et al (2016) Immunosuppressive drugs discontinuation in noninfectious uveitis from real-life clinical practice: a survival analysis. Am J Ophthalmol 169:169–178

    Google Scholar 

  106. Lerman MA, Lewen MD, Kempen JH, Mills MD (2015) Uveitis reactivation in children treated with tumor necrosis factor alpha inhibitors. Am J Ophthalmol 160:193200

    Google Scholar 

  107. Kalinina Ayuso VK, van de Winkel EL, Rothova A et al (2011) Relapse rate of uveitis post-methotrexate treatment in juvenile idiopathic arthritis. Am J Ophthalmol 151:217–222

    PubMed  Google Scholar 

  108. Shakoor A, Esterberg E, Acharya NR (2014) Recurrence of uveitis after discontinuation of infliximab. Ocul Immunol Inflamm 22:96–101

    CAS  PubMed  Google Scholar 

  109. Borrego-Sanz L, Abásolo L, López-Abad C et al (2018) Disease remission in children and adolescents with intermediate uveitis: a survival analysis. Ophthalmologica 239:151–158

    PubMed  Google Scholar 

  110. Kempen JH, Gewaily DY, Newcomb CW, Liesegang TL, Kaçmaz RO, Levy-Clarke GA, Nussenblatt RB, Rosenbaum JT, Sen HN, Suhler EB, Thorne JE, Foster CS, Jabs DA, Payal A, Fitzgerald TD, Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Research Group (2016) Remission of Intermediate Uveitis: Incidence and Predictive Factors. Am J Ophthalmol 164:110–117

    PubMed  PubMed Central  Google Scholar 

  111. Becker M, Davis J (2005) Vitrectomy in the treatment of uveitis. Am J Ophthalmol 140:1096–1105

    PubMed  Google Scholar 

  112. Quinones K, Choi JY, Yilmaz T et al (2010) Pars plana vitrectomy versus immunomodulatory therapy for intermediate uveitis: A prospective, randomized pilot study. Ocul Immunol Inflamm 18:411–417

    PubMed  Google Scholar 

  113. Heiligenhaus A, Bornfeld N, Foerster MH, Wessing A (1994) Long-term results of pars plana vitrectomy in the management of complicated uveitis. Br J Ophthalmol 78:549–554

    CAS  PubMed  PubMed Central  Google Scholar 

  114. Park SE, Mieler WF, Pulido JS (1995) 2 peripheral scatter photocoagulation for neovascularization associated with pars planitis. Arch Ophthalmol 113:1277–80

    CAS  PubMed  Google Scholar 

  115. Pulido JS, Mieler WF, Walton D, Kuhn E, Postel E, Hartz A et al (1998) Results of peripheral laser photocoagulation in pars planitis. Trans Am Ophthalmol Soc 96:127–137

    CAS  PubMed  PubMed Central  Google Scholar 

  116. Ganesh SK, Babu K, Biswas J (2004) Phacoemulsification with intraocular lens implantation in cases of pars planitis. J Cataract Refract Surg 30:2072–2076

    PubMed  Google Scholar 

  117. Grzybowski A, Kanclerz P, Pleyer U (2017) Challenges with cataract surgery in pars planitis patients. Graefes Arch Clin Exp Ophthalmol 255:1483–1484

    PubMed  PubMed Central  Google Scholar 

  118. Kaufman AH, Foster CS (1993) Cataract extraction in patients with pars planitis. Ophthalmology 100:1210–1217

    CAS  PubMed  Google Scholar 

  119. Friedman DS, Holbrook JT, Ansari H et al (2013) Risk of elevated intraocular pressure and glaucoma in patients with uveitis: results of the multicenter uveitis steroid treatment trial. Ophthalmology 120:1571–1579

    PubMed  PubMed Central  Google Scholar 

  120. Sen HN, Vitale S, Gangaputra SS et al (2014) Periocular corticosteroid injections in uveitis: effects and complications. Ophthalmology 121:2275–2286

    PubMed  PubMed Central  Google Scholar 

Download references

Redatkionskomitee

Prof. Dr. med. Christoph Deuter

Prof. Dr. med. Justus G. Garweg

Prof. Dr. med. Arnd Heiligenhaus, F.E.B.O. (federführend)

Prof. Dr. med. Carsten Heinz, F.E.B.O.

Prof. Dr. med. Uwe Pleyer, F.E.B.O.

Author information

Authors and Affiliations

    Consortia

    Berufsverband der Augenärzte Deutschlands e. V. (BVA)

    Deutsche Ophthalmologische Gesellschaft (DOG)

    Ethics declarations

    Interessenkonflikt

    Tabellarische Zusammenfassung der Erklärungen über Interessenkonflikte gemäß dem Formular der AWMF und des ÄZQ zur Erklärung von Interessenkonflikten im Rahmen von NVL(Nationale VersorgungsLeitlinien)-Verfahren (Stand 28.05.2018) (s. Tab. 3 im Anhang).

    Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.

    The supplement containing this article is not sponsored by industry.

    Anhang

    Anhang

    Im Folgenden sind die Interessenerklärungen als tabellarische Zusammenfassung dargestellt sowie die Ergebnisse der Interessenkonfliktbewertung und Maßnahmen, die nach Diskussion der Sachverhalte von der LL-Gruppe beschlossen und im Rahmen der Konsensuskonferenz umgesetzt wurden.

    Tab. 3 Tabelle zur Erklärung von Interessen und Umgang mit Interessenkonflikten
    Full size table

    Rights and permissions

    Reprints and permissions

    About this article

    Check for updates. Verify currency and authenticity via CrossMark

    Cite this article

    Berufsverband der Augenärzte Deutschlands e. V. (BVA)., Deutsche Ophthalmologische Gesellschaft (DOG). Leitlinie Nr. 24a Uveitis intermedia. Ophthalmologe 118 (Suppl 1), 16–30 (2021). https://doi.org/10.1007/s00347-020-01171-w

    Download citation

    • Published:

    • Issue Date:

    • DOI: https://doi.org/10.1007/s00347-020-01171-w

    Search

    Navigation